Kimberly A. Aron

Array ( [id] => 17383965 [patent_doc_number] => 20220031817 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-03 [patent_title] => ENHANCED THERAPEUTIC USAGE OF A PURINE NUCLEOSIDE PHOSPHORYLASE OR NUCELOSIDE HYDROLASE PRODRUG [patent_app_type] => utility [patent_app_number] => 17/502101 [patent_app_country] => US [patent_app_date] => 2021-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9283 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17502101 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17426855 [patent_doc_number] => 20220054563 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-24 [patent_title] => DOSING REGIME AND FORMULATIONS FOR TYPE B ADENOVIRUSES [patent_app_type] => utility [patent_app_number] => 17/448549 [patent_app_country] => US [patent_app_date] => 2021-09-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21355 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17448549 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17519285 [patent_doc_number] => 20220105133 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-07 [patent_title] => TUMOR INFILTRATING LYMPHOCYTES AND METHODS OF THERAPY [patent_app_type] => utility [patent_app_number] => 17/481404 [patent_app_country] => US [patent_app_date] => 2021-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48740 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17481404 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20548942 [patent_doc_number] => 12559724 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-02-24 [patent_title] => Genetically modified mesenchymal stem cell expressing Klotho [patent_app_type] => utility [patent_app_number] => 17/447975 [patent_app_country] => US [patent_app_date] => 2021-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16268 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17447975 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17441933 [patent_doc_number] => 20220062438 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-03 [patent_title] => CODON OPTIMIZED REP1 GENES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/463262 [patent_app_country] => US [patent_app_date] => 2021-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16359 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17463262 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17275739 [patent_doc_number] => 20210381937 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-09 [patent_title] => FIXATION OF A BIOLOGICAL MATERIAL [patent_app_type] => utility [patent_app_number] => 17/411675 [patent_app_country] => US [patent_app_date] => 2021-08-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15185 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17411675 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17293377 [patent_doc_number] => 20210389216 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-16 [patent_title] => FIXATION OF A BIOLOGICAL MATERIAL [patent_app_type] => utility [patent_app_number] => 17/411667 [patent_app_country] => US [patent_app_date] => 2021-08-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15175 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17411667 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17299944 [patent_doc_number] => 20210395783 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-23 [patent_title] => PRIMARY CELL GENE EDITING [patent_app_type] => utility [patent_app_number] => 17/400974 [patent_app_country] => US [patent_app_date] => 2021-08-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43319 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 164 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17400974 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19840156 [patent_doc_number] => 12252525 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-18 [patent_title] => Chimeric T cell receptors, nucleic acids, and methods of making and using the same [patent_app_type] => utility [patent_app_number] => 17/387347 [patent_app_country] => US [patent_app_date] => 2021-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 68 [patent_figures_cnt] => 51 [patent_no_of_words] => 10397 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17387347 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17212801 [patent_doc_number] => 20210346137 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-11 [patent_title] => METHOD FOR INJECTABLE DELIVERY OF A THERAPEUTIC AGENT INTO A FISH EMBRYO [patent_app_type] => utility [patent_app_number] => 17/361220 [patent_app_country] => US [patent_app_date] => 2021-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4300 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17361220 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17170738 [patent_doc_number] => 20210324408 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-21 [patent_title] => TRANSPOSITION OF NUCLEIC ACID CONSTRUCTS INTO EUKARYOTIC GENOMES WITH A TRANSPOSASE FROM AMYELOIS [patent_app_type] => utility [patent_app_number] => 17/339597 [patent_app_country] => US [patent_app_date] => 2021-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30672 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17339597 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18005346 [patent_doc_number] => 20220364112 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-17 [patent_title] => ONCOLYTIC VIRUS FOR TREATING BRAIN TUMORS USING RECOMBINANT NEWCASTLE DISEASE VIRUS INTO WHICH NEWCASTLE DISEASE VIRUS VECTOR-BASED PTEN GENE IS INSERTED AND COMPOSITION FOR TREATING BRAIN TUMORS USING SAME [patent_app_type] => utility [patent_app_number] => 17/616762 [patent_app_country] => US [patent_app_date] => 2021-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9733 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17616762 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20729104 [patent_doc_number] => 12636348 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-05-26 [patent_title] => Treatment of ocular neovascularization using anti-vegf proteins [patent_app_type] => utility [patent_app_number] => 17/328705 [patent_app_country] => US [patent_app_date] => 2021-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 47 [patent_figures_cnt] => 51 [patent_no_of_words] => 35789 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 176 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17328705 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17082417 [patent_doc_number] => 20210277423 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-09 [patent_title] => THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/Cas SYSTEMS [patent_app_type] => utility [patent_app_number] => 17/327625 [patent_app_country] => US [patent_app_date] => 2021-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 68041 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17327625 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17156425 [patent_doc_number] => 20210317476 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-14 [patent_title] => FOWL ADENOVIRUS 9 (FADV-9) VECTOR SYSTEM AND ASSOCIATED METHODS [patent_app_type] => utility [patent_app_number] => 17/244079 [patent_app_country] => US [patent_app_date] => 2021-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16115 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17244079 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17037140 [patent_doc_number] => 20210254098 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-19 [patent_title] => POLYEPITOPE CONSTRUCTS FOR USE IN IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 17/241546 [patent_app_country] => US [patent_app_date] => 2021-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9061 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17241546 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17256883 [patent_doc_number] => 20210369868 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-02 [patent_title] => Optimized Liver-Specific Expression Systems for FVIII and FIX [patent_app_type] => utility [patent_app_number] => 17/240845 [patent_app_country] => US [patent_app_date] => 2021-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22543 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17240845 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18449680 [patent_doc_number] => 20230190956 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => METHODS FOR PREVENTING INDUCTION OF IMMUNE RESPONSES TO THE TRANSDUCED CELLS EXPRESSING A TRANSGENE PRODUCT AFTER OCULAR GENE THERAPY [patent_app_type] => utility [patent_app_number] => 17/996987 [patent_app_country] => US [patent_app_date] => 2021-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15433 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17996987 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19809706 [patent_doc_number] => 12241078 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-04 [patent_title] => AAV vectors for retinal and CNS gene therapy [patent_app_type] => utility [patent_app_number] => 17/194009 [patent_app_country] => US [patent_app_date] => 2021-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 33 [patent_no_of_words] => 53109 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 142 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17194009 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16657771 [patent_doc_number] => 20210054407 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-25 [patent_title] => Dry Transfection Compositions and Methods for Making and Using the Same [patent_app_type] => utility [patent_app_number] => 17/090110 [patent_app_country] => US [patent_app_date] => 2020-11-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13534 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17090110 [rel_patent_id] =>[rel_patent_doc_number] =>)